Immune SystemAnti-inflammatory

Thymosin Alpha-1

What is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) modulates, enhances, and restores immune function by promoting T-lymphocyte maturation (CD4+/CD8+), activating NK and dendritic cells, and balancing inflammation. Reduces pro-inflammatory cytokines (IL-1β, TNF-α). Shows promise in chronic viral infections, immunocompromised states, autoimmune diseases, and as cancer adjuvant. FDA-approved in 35+ countries (brand: Thymalfasin) for Hepatitis B/C, but NOT FDA-approved in USA. NOTE: Lack of standardized manufacturing/quality control in many commercial products - use under medical supervision only.

Benefits

  • Enhances T-cell Function and Maturation
  • Activates NK Cells and Dendritic Cells
  • Modulates Inflammation
  • Antiviral Properties (Hep B/C, HIV)
  • Improves Vaccine Response
  • Supports Cancer Immunotherapy

Typical Dosage

  • Standard: 1.6mg twice weekly for up to 24 weeks
  • Chronic viral: 1.5mg twice weekly, 6-12 months
  • Cancer support: 1.5-3mg, 2-3x weekly during treatment
  • Acute viral: 1.5mg daily for 5-10 days
  • Subcutaneous injection

Side Effects

  • Generally well-tolerated
  • Mild injection site reactions
  • Rare allergic reactions
  • Requires medical supervision

Negative Interactions

  • Unpredictable immunomodulatory effects
  • NOT FDA approved in USA (off-label use)
HomeLibraryResearchFavoritesToolsVisuals